stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 128.36 |
+8 more quarters Free account |
P/S ratio |
6.40 | 5.56 | 5.44 | 5.41 | |
P/FCF ratio |
0.00 | 0.00 | 207.39 | 0.00 | |
P/Operating CF |
(195.68) | (39.65) | 200.15 | (112.14) | |
P/B ratio |
5.39 | 4.65 | 4.65 | 10.59 | |
Price to Tangible BV |
5.57 | 4.81 | 4.81 | 11.51 | |
EV/Sales |
5.83 | 4.97 | 5.06 | 4.66 | |
EV/EBITDA |
0.00 | 0.00 | 235.25 | 38.79 | |
EV/Operating CF |
(30.65) | (120.29) | 137.05 | 537.99 | |
EV/FCF |
(27.91) | (83.33) | 192.86 | (615.37) | |
Quick Ratio |
0.00 | 3.59 | 3.68 | 5.21 | |
Current Ratio |
4.32 | 4.26 | 4.64 | 6.28 | |
Net Debt/EBITDA |
— | 5.80 | 5.74 | (17.74) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.68 | 0.68 | 0.80 | 0.68 | |
Operating CF/Net income |
0.98 | 1.43 | (0.37) | 3.26 | |
Capex/Depreciation |
0.00 | (0.87) | (0.26) | (0.19) | |
Interest Coverage |
— | (15.23) | — | — | |
Research and Development Expense of Revenue |
0.00% | 65.75% | 29.92% | (0.30%) | |
Selling, General and Administrative Expense of Revenue |
0.00% | 74.29% | 94.84% | 75.46% | |
Intangible Assets out of Total Assets |
0.00 | 0.02 | 0.03 | 0.02 | |
Share Based Compensation of Revenue |
5.27% | 7.13% | 11.47% | 12.36% | |
Graham Net Nets |
0.11 | 0.13 | 0.10 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.91 | |
Earnings Yield |
(3.82%) | (3.03%) | (1.08%) | 0.78% | |
Free Cash Flow Yield |
(3.26%) | (1.07%) | 0.48% | (0.14%) | |
Revenue per Share |
0.31 | 0.29 | 0.25 | 0.42 | |
Operating CF per Share |
(0.04) | (0.17) | 0.03 | (0.06) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.18) | 0.03 | (0.06) | |
Cash per Share |
0.00 | 0.74 | 0.55 | 1.04 | |
Shareholders Equity per Share |
0.00 | 1.64 | 1.50 | 2.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 1.64 | 1.50 | 2.11 | |
Free Cash Flow |
(4.08) | (18.01) | 3.00 | (5.75) | |
Working Capital |
94.82 | 93.41 | 71.94 | 125.58 | |
Capital Expenditures |
(0.10) | (1.28) | (0.18) | (0.13) | |
Net Current Asset Value |
88.22 | 87.74 | 66.70 | 117.96 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 47.30 | |
Capex to Sales |
0.00 | 0.04 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 54.91 | |
| Other line items | |||||
Average Receivables |
— | 26.44 | 21.69 | 28.04 | |
Average Payables |
1.60 | 0.65 | 0.19 | 0.72 | |
Average Inventory |
10.54 | 10.14 | 9.62 | 8.25 | |
Average Assets |
180.32 | 175.95 | 145.90 | 172.58 | |
Average Common Equity |
140.97 | 135.97 | 120.64 | 78.97 |
Columns are period end dates · fundamentals updated 6 Nov 2026